跳至主要内容
临床试验/EUCTR2012-001288-58-NL
EUCTR2012-001288-58-NL进行中(未招募)不适用

Boosting oxytocin after trauma: The effects of intranasal oxytocin administration on emotional and motivational brain processes in PTSD - The effect of oxytocin in PTSD

Academic Medical Center0 个研究点开始时间: 2012年3月27日最近更新:
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Age 18 – 65 years
  • Capable to read and comprehend the Dutch language
  • Eligibility for MRI (i.e. no metals, pacemakers or claustrophobia)
  • Exposed to a potentially traumatic event, according to PTSD A1 criterion in the DSM-IV (minimal 1 month ago), quantified as a score of 1 or higher on the Life Events Checklist (LEC).
  • PTSD patients:
  • Current PTSD diagnosis
  • CAPS score = 45
  • Traumatized healthy controls:
  • CAPS-score < 15
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 80
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Any severe or chronic systemic disease
  • Current psychotic, bipolar, substance-related, severe personality disorder, or mental retardation
  • Current severe depressive disorder
  • Prominent current suicidal risk or homicidal ideation
  • Severe cognitive impairment or a history of organic mental disorder
  • History of neurological disorders (e.g., traumatic brain injury, seizure history)
  • Reports of ongoing traumatization (e.g., in case of partner violence as index adult trauma)
  • Evidence of clinically significant and unstable medical conditions in which OT administration is contra-indicative such as cardiovascular, gastro-intestinal, pulmonary, severe renal, endocrine or hematological disorders, glaucoma, history of epilepsy, or a stroke or myocardial infarction within the past year
  • Use of certain medication: prostaglandins, certain anti-migraine medications (ergot alkaloids), ß-adrenergic receptor-blocking agents, systemic glucocorticoids and psychopharmacological medication.
  • Sensitivity or allergy for OT or its components (e.g. methylhydroxybenzoate and propylhydroxybenzoate)
  • Female participants: pregnancy and breast feeding (NB. Female participants with childbearing potential must have a negative pregnancy test).
  • Traumatized healthy controls only:
  • (lifetime history of) PTSD diagnosis, major depressive disorder.
  • current DSM-IV axis 1 disorder

研究者

发起方
Academic Medical Center

相似试验

The effect of oxytocin in PTSD | 临床试验